Ocimene

Ocimene has more than one naming detail

Ocimene is an acyclic monoterpene. Cannabis plant-chemistry work identified (E)-beta-ocimene among terpene products made in resin-producing trichomes. A report may use beta-ocimene or specify its geometric isomer, so the exact wording matters.

The parasite study stayed in cell models

A 2023 study tested isolated beta-ocimene against Leishmania amazonensis parasites and macrophage cultures. It measured parasite growth, membrane changes and inflammatory signalling in those laboratory systems. No people or cannabis-based medicinal products were tested.

The plant study adds a different kind of evidence: it identifies E-beta-ocimene as a product of cannabis resin chemistry. A secondary plant-chemistry chart helps with the name, but neither source provides a patient outcome.

Ocimene results describe composition

“Ocimene” or “beta-ocimene” on a laboratory report identifies a reported constituent. It does not show that a product contains the same isomer, concentration or surrounding compounds as the parasite experiment. NHS medical-cannabis information supplies the prescribed-product context. The cited studies do not support an anti-infective or anti-inflammatory claim for a labelled product.

Related conditions

• Migraine and headache
• Anxiety disorders

Sources

• Cytotoxic and antileishmanial effects of β-ocimene (primary parasite and cell/laboratory study, PMID 37259336, DOI 10.3390/ph16020183).
• Terpene synthases from Cannabis sativa (primary cannabis plant-chemistry study, PMID 28355238, DOI 10.1371/journal.pone.0173911).